Metronidazole Vioser

Metronidazole, the active ingredient in Metronidazole Vioser, is a nitroimidazole antibiotic presented as an intravenous solution for intravenous use. It treats anaerobic bacterial and protozoal infections in adults and children when prescribed by a qualified healthcare professional. It is indicated for conditions such as bacterial vaginosis, trichomoniasis, amoebiasis, and Clostridioides difficile infection.

GNH USA supplies Metronidazole Vioser as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to strict quality standards and provides products to a global network of healthcare providers.

Metronidazole is used to treat infections caused by anaerobic bacteria and certain protozoa. - Anaerobic bacterial infections: eradicates susceptible anaerobes, reducing infection severity. - Bacterial vaginosis: restores normal vaginal flora by eliminating overgrowth of anaerobic bacteria. - Trichomoniasis: eliminates Trichomonas vaginalis, relieving symptoms and preventing transmission. - Amoebiasis: destroys Entamoeba histolytica trophozoites, treating intestinal and extra‑intestinal disease. - Clostridioides difficile infection: reduces toxin‑producing C. difficile, aiding resolution of colitis.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset that may resolve without treatment. - Metallic taste: transient metallic sensation in the mouth. - Headache: mild to moderate headache during therapy. - Diarrhea: loose stools that may accompany treatment.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or anaphylaxis requiring immediate medical attention. - Peripheral neuropathy: tingling or numbness in extremities, potentially irreversible. - Seizures: rare occurrence of convulsions, especially in high doses or renal impairment. - Hepatic toxicity: elevated liver enzymes or jaundice indicating liver injury.

Before initiating Metronidazole therapy, consider the following precautions to ensure safe use. - Renal and hepatic function: assess kidney and liver status, adjust use if impairment is present. - Central nervous system disorders: use cautiously in patients with seizures or neuropathy history. - Alcohol consumption: avoid alcohol during treatment and for at least 48 hours after completion to prevent disulfiram‑like reactions. - Pregnancy and lactation: evaluate risk‑benefit, as it is classified Category B; use only if clearly needed. - Concomitant medications: monitor for interactions that may increase toxicity or reduce efficacy. - Store at room temperature: keep in original container, protect from light and moisture.

Metronidazole can interact with several medicines; awareness of major and moderate interactions helps manage therapy safely.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, nausea, vomiting, and tachycardia. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: may raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce hormonal efficacy, increasing risk of unintended pregnancy. - Cimetidine: can increase metronidazole plasma concentrations, enhancing side effects.